Granules India Limited has released its Monitoring Agency Report for the quarter ended March 31, 2026. The report confirms that there have been no deviations in the utilization of proceeds raised through the company’s preferential issue. As of the end of the quarter, the company successfully utilized ₹218.14 crore of the total proceeds received, with all deployments aligned with the objectives outlined in the original offer document.
Utilization of Preferential Issue Proceeds
As of March 31, 2026, Granules India Limited reported total proceeds received from the preferential issue amounting to ₹665.63 crore. The funds were raised through the issuance of 51,28,205 equity shares and 2,50,00,000 convertible warrants. The company has maintained complete transparency regarding the usage of these funds, with ₹218.14 crore already deployed towards project objectives.
Breakdown of Fund Allocation
The deployed funds were directed towards key operational areas. Notably, ₹44.21 crore was utilized for General Corporate Purposes, specifically covering salary payments for the months of February and March 2026. Furthermore, ₹5.01 crore was channeled into capital expenditure for fixed assets and infrastructure, while ₹16.17 crore supported manufacturing operating expenses such as power, fuel, and equipment maintenance.
Strategic Investments and Financial Standing
A significant portion of the capital continues to be deployed into subsidiary operations. The company invested ₹400.00 crore in its wholly-owned subsidiary, Granules Life Sciences Private Limited, during the quarter. The remaining unutilized funds are effectively managed through low-risk liquid instruments, including fixed deposits, earning returns that contribute to the company’s financial efficiency. The implementation of all stated objects remains on schedule, with no delays or deviations reported.
Source: BSE
